22 Comments

  1. So the stock went through a terrible day today. If your new, I would get in ASAP. The price is unlikely to get better. If you’re holding, don’t panic sell, this company is undervalued

  2. ISR is debt free! ISR exceeded the US Biotechs industry which returned 28% over the past year. ISR has not had any debt for past 5 years! ISR exceeded the US Market which returned 21% over the past year. Earnings are forecast to grow 67.98% per year. ISR's revenue (28.2% per year) is forecast to grow faster than 20% per year. ISR's management team is considered experienced (2.3 years average tenure). ISR's revenue (28.2% per year) is forecast to grow faster than the US market (10% per year). ISR's board of directors are considered experienced (3.8 years average tenure). ISR insiders have bought more shares than they have sold in the past 3 months.

  3. awesome. Im kinda new in this small stocks. Would this be a long term investment and could it potentially become really big or should I sell it when it reaches like 2-3 dollars?

Leave a Reply

Your email address will not be published.


*